Botanix Pharmaceuticals Limited
BXPHF
$0.04
$0.0010.88%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.25M | 8.95M | 3.68M | 2.50M | 1.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.25M | 8.95M | 3.68M | 2.50M | 1.36M |
| Cost of Revenue | 5.53M | 3.97M | 2.42M | 2.48M | 2.56M |
| Gross Profit | 8.72M | 4.99M | 1.26M | 20.60K | -1.20M |
| SG&A Expenses | 61.54M | 57.22M | 53.22M | 38.80M | 24.72M |
| Depreciation & Amortization | 1.50M | 1.48M | 1.47M | 1.12M | 781.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.57M | 62.66M | 57.10M | 42.40M | 28.06M |
| Operating Income | -54.33M | -53.71M | -53.42M | -39.90M | -26.70M |
| Income Before Tax | -56.94M | -56.11M | -55.60M | -40.59M | -25.94M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -56.94 | -56.11 | -55.60 | -40.59 | -25.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.94M | -56.11M | -55.60M | -40.59M | -25.94M |
| EBIT | -54.33M | -53.71M | -53.42M | -39.90M | -26.70M |
| EBITDA | -52.82M | -52.23M | -51.96M | -38.78M | -25.92M |
| EPS Basic | -0.03 | -0.03 | -0.03 | -0.02 | -0.01 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 |
| EPS Diluted | -0.03 | -0.03 | -0.03 | -0.02 | -0.01 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 7.67B | 7.53B | 7.38B | 7.07B | 6.76B |
| Average Diluted Shares Outstanding | 7.67B | 7.53B | 7.38B | 7.07B | 6.76B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |